FLYW Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against Flywire Corporation

SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Flywire Corporation (NASDAQ: FLYW) securities between February 28, 2024 and February 25, 2025. Flywire operates as a payments-enablement and software company in the U.S. and internationally. For more information, submit […]

Pole Star Global erwirbt Clearwater Dynamics und erweitert damit die Echtzeit-Risikoaufklärung für Schifffahrts- und Versicherungsmärkte

LONDON, 12. August 2025 /PRNewswire/ — Pole Star Global, der Weltmarktführer für maritime Informationslösungen, hat heute die Übernahme von Clearwater Dynamics bekannt gegeben, einem britischen Innovator im Bereich Echtzeit-Risikoinformationen für die Schifffahrt und Entwickler von Coral — der führenden Plattform für das Management von Risiken in der Seeversicherung. Continue Reading Clearwater Dynamics Logo Diese strategische […]

ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ — Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 […]

BarrierBreak im Gartner® Market Guide for Digital Accessibility 2025 ausgezeichnet

MUMBAI, Indien, 13. August 2025 /PRNewswire/ — BarrierBreak, ein weltweit führender Anbieter von Lösungen für digitale Barrierefreiheit, ist stolz darauf, als repräsentativer Anbieter in den Gartner® Market Guide for Digital Accessibility 2025 aufgenommen worden zu sein. Diese Auszeichnung unterstreicht die einzigartige Fähigkeit von BarrierBreak, skalierbare, menschenzentrierte Lösungen für digitale Barrierefreiheit anzubieten, die auf Technologie basieren und von […]

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

NEW YORK, Aug. 12, 2025 /PRNewswire/ — Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may reduce knee pain caused by osteoarthritis. This approach may also slow progression of the condition, an uncurable disease in which the cartilage cushion inside a joint breaks down. Continue Reading Led […]

Simon Property Group Sells $1.5 Billion of Senior Notes

INDIANAPOLIS, Aug. 12, 2025 /PRNewswire/ — Simon®, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, announced today that its majority-owned operating partnership subsidiary, Simon Property Group, L.P. (the “Operating Partnership”), has agreed to sell: $700.0 million aggregate principal amount of its 4.375% Notes due 2030, and […]

Lockheed Martin Corporation Stockholders with Large Losses are Encouraged to Contact Robbins LLP Regarding the LMT Class Action Lawsuit

SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025. Lockheed Martin is an aerospace defense company. For more information, submit a form, email attorney Aaron Dumas, Jr., […]

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

–         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.  –          ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination […]